Follow
Edward R Scheffer Cliff, MBBS (Hons) MPH
Edward R Scheffer Cliff, MBBS (Hons) MPH
Verified email at bwh.harvard.edu - Homepage
Title
Cited by
Cited by
Year
Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition
TE Lew, VS Lin, ER Cliff, P Blombery, ER Thompson, SM Handunnetti, ...
Blood Advances 5 (20), 4054-4058, 2021
502021
Neonatal diabetes caused by a homozygous KCNJ11 mutation demonstrates that tiny changes in ATP sensitivity markedly affect diabetes risk
N Vedovato, E Cliff, P Proks, V Poovazhagi, SE Flanagan, S Ellard, ...
Diabetologia, 1-7, 2016
302016
High Cost of Chimeric Antigen Receptor T-Cells: Challenges and Solutions
ERS Cliff, AH Kelkar, DA Russler-Germain, FA Tessema, AJN Raymakers, ...
American Society of Clinical Oncology Educational Book 43, e397912, 2023
182023
Acknowledging infection risk in bispecific antibody trials in the treatment of multiple myeloma
ERS Cliff, G Reynolds, R Popat, BW Teh, AS Kesselheim, GR Mohyuddin
Journal of Clinical Oncology 41 (10), 1949-1951, 2023
132023
Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis.
G Reynolds, ERS Cliff, GR Mohyuddin, R Popat, S Midha, M Ng Liet Hing, ...
Blood Advances, 2023
122023
Hypocalcaemia following denosumab in prostate cancer: A clinical review
LH Lau, ERS Cliff, V Wong, H Wong, N Torkamani, A Eer, A Weickhardt, ...
Clinical Endocrinology 92 (6), 495-502, 2020
102020
Permanent neonatal diabetes: combining sulfonylureas with insulin may be an effective treatment
S Misra, N Vedovato, E Cliff, E De Franco, AT Hattersley, FM Ashcroft, ...
Diabetic Medicine 35 (9), 1291-1296, 2018
92018
T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated disease
TE Lew, ERS Cliff, M Dickinson, CS Tam, JF Seymour, P Blombery, ...
Bone Marrow Transplantation 56 (11), 2857-2859, 2021
72021
Overall survival as a primary end point in multiple myeloma trials
ERS Cliff, GR Mohyuddin
Nature Reviews Clinical Oncology 19 (9), 565-566, 2022
62022
Teclistamab in Relapsed or Refractory Multiple Myeloma
ERS Cliff, H Mian, GR Mohyuddin
The New England journal of medicine 387 (18), 1721-1722, 2022
52022
Achieving self-sufficiency: training Australia’s future medical workforce
B Fernandes, ERS Cliff, A Chowdhury
Australian Health Review, 2017
52017
Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: no ordinary subgroup analysis
DA Russler-Germain, ERS Cliff, NL Bartlett
Blood 142 (25), 2216-2219, 2023
42023
Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey
GR Mohyuddin, R Chakraborty, ERS Cliff, BA Derman
eClinicalMedicine 65, 2023
42023
Melflufen: post-hoc subgroup analyses and the US FDA Oncologic Drugs Advisory Committee
ERS Cliff, M Janakiram, AS Kesselheim
The Lancet Haematology 10 (5), e314-e317, 2023
42023
CARTIFAN-1: Concerning Fatal Adverse Events with Global use of Chimeric Antigen Receptor–T-Cell Therapy in Multiple Myeloma
S Al Hadidi, ERS Cliff
European Journal of Cancer, 2022
42022
Frontline polatuzumab vedotin for diffuse large B‐cell lymphoma: A survey of clinician impressions
A Major, ERS Cliff, DA Ermann, U Durani, DA Russler‐Germain
EJHaem 3 (3), 930-935, 2022
42022
Cost-effectiveness of CD19 chimeric antigen receptor T-cell (CAR-T) therapy versus autologous stem cell transplantation (ASCT) for high-risk diffuse large B-cell lymphoma …
AH Kelkar, ERS Cliff, CA Jacobson, GA Abel, R Redd, S Dijk, E Krijkamp, ...
Journal of Clinical Oncology 40 (16_suppl), 7537-7537, 2022
42022
National Comprehensive Cancer Network Guideline Recommendations of Cancer Drugs With Accelerated Approval
ERS Cliff, RS Rome, AS Kesselheim, BN Rome
JAMA Network Open 6 (11), e2343285-e2343285, 2023
32023
Ensuring Ethical Postprogression Therapy for Patients in Randomized Trial Control Arms
ERS Cliff, AS Kesselheim, WB Feldman
Journal of Clinical Oncology, JCO. 22.02675, 2023
32023
Is aggressive treatment of smoldering myeloma the path to curing myeloma?
R Chakraborty, S Al Hadidi, ERS Cliff, GR Mohyuddin
Blood Advances, 2023
32023
The system can't perform the operation now. Try again later.
Articles 1–20